Concepedia

Celine Pitou

CP

Statistics

Publications

17

Citations

899

H-Index

15

Active since

2007

Affiliations

Eli Lilly (United States)(Current)

Eli Lilly (United Kingdom)

The University of Texas MD Anderson Cancer Center

Tennessee Oncology

University of Utah

Celine Pitou is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and cancer pharmacology.

Publications per year

2007–2022

17

Publications

17

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

L. Buéno, Dinesh P. de Alwis, Celine Pitou et al. · European Journal of Cancer · 2007 · 202 citations

, , +15

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Amita Patnaik, Paul Haluska, Anthony W. Tolcher et al. · Clinical Cancer Research · 2015 · 138 citations

, , +14

Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma

Johanna C. Bendell, Valérie André, Alan L. Ho et al. · Clinical Cancer Research · 2018 · 68 citations · Full text

, , +15

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F

Liandong Ma, Joshua R. Clayton, Richard A. Walgren et al. · Blood Cancer Journal · 2013 · 66 citations · Full text

, , +16

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer

Ignace Vergote, Florian Heitz, Paul Buderath et al. · Gynecologic Oncology · 2019 · 66 citations

, , +17

1–5 of 17